Dr. Bernard Harris logged 437 hours in space and was the first Black astronaut to walk in space. Photo courtesy University of Houston.

University of Houston alumnus Dr. Bernard Harris, who was the first Black astronaut to walk in space, is being inducted into the Astronaut Hall of Fame.

The induction ceremony will be held May 31 at the Kennedy Space Center Visitor Complex in Cape Canaveral, Florida.

“Being inducted into the Astronaut Hall of Fame is a tremendous honor, made even more special by the fact that it comes from my peers,” Harris says in a UH news release. “This recognition isn’t just about my accomplishments. It is also a testament to the teamwork and dedication of everyone who shared this amazing journey with me along the way.”

Harris and former astronaut Peggy Whitson, who spent more time in space than any other woman, will join 109 other astronauts inducted into the Hall of Fame. The Astronaut Scholarship Foundation selects the honorees.

Harris, a Texas native who spent much of his childhood in Houston and San Antonio, earned a bachelor’s degree in biology from UH in 1978 and went on to medical school. After completing his residency at the Mayo Clinic and a fellowship at NASA’s Ames Research Center, he joined NASA as a clinical scientist and flight surgeon. He was chosen for the astronaut training program in 1990 and became an astronaut a year later.

In 1993, Harris flew his first mission on Space Shuttle Columbia, during which he conducted research and experiments in physical and life sciences. During his second mission, on Space Shuttle Discovery in 1995, Harris became the first Black astronaut to walk in space. In total, Harris logged 437 hours in space and traveled over 7 million miles.

After leaving NASA, Harris founded the Houston-based investment firm Vesalius Ventures to support emerging medical technology and devices. He also focuses on philanthropy through The Harris Foundation, a Houston-based nonprofit that empowers socially and economically disadvantaged students and communities.

“Space exploration has always been about pushing boundaries, inspiring future generations and proving that the impossible is achievable,” Harris says. “I am grateful for the opportunities that I have been given, and I hope to continue empowering others to reach for the stars.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”